ARKT

ARK DIET Q4 Buffer ETF

ARK · $2.0m in assets, October 8, 2026

An actively managed ETF: uses options to cap gains and cushion losses over 12-month periods running October 1 to September 30. The targeted result applies in full only to shares held from start to end of a period.

ARKT, the ARK DIET Q4 Buffer ETF, is a $2 million ETF whose main story is pure narrative flow. Over the past year it returned −3.3%, against +16.8% for broad US ETFs. Figures to October 2, 2026; past performance, not a recommendation.

ARKT · the ETFFRI OCT 2Market price total return
−2.4% a yearTotal return since launch, October 2025
−3.3%Last 12 months
+6.8%Year to date
18.1%Volatility since launch

The narrative it carries

Its main narrative, at 0.7 of its exposure.

Pure narrative flow →

Disruptive innovation, online consumers, betting and stocks chosen by social sentiment: where the retail crowd puts its money.

Pure narrative flow · the narrative this week
53.0WARM level, 9 of 22
last four weeks
99ETFs carry it
98.2%held by the top five
ARKKlargest holder, 91.7%
$93.4 bncapital, 13th of 22

The band is where this narrative’s level sits among the 22 this week. QUIET means less talked about, not falling.

Who owns the capital
ARKK 91.7%IBUY 2.0%BUZZ 1.7%MILN 1.4%SOCL 1.4%94 other ETFs 1.8%98.2%top five
#ETFSHAREASSETS1 YEARCOST
1ARKK91.7%$7.92bn+0.7%0.75%
2IBUY2.0%$120.1m−13.8%0.65%
3BUZZ1.7%$102.7m+3.4%0.76%
4MILN1.4%$87.1m−14.8%0.50%
5SOCL1.4%$85.0m−28.3%0.65%
94 other ETFs1.8%
ARKT: 0.0%

Share is each ETF’s slice of the capital carrying this narrative. 1 year is market price total return; cost is the expense ratio. See all 99 ETFs on the narrative page →

Also carries: The biology trade →

Health care from drugmakers and insurers to genomics: the science that gets approved, and who pays for it.

Exposure 0.3 · level 41.2 QUIET, 20th of 22 · ARKT holds 0.0% of its capital

FRI OCT 2MARKET PRICE TOTAL RETURN

1M3MYTD1Y3Y*5Y*
ARKT+2.6%+4.2%+6.8%−3.3%––
Pure narrative flowits narrative+6.7%+9.4%+14.8%−0.4%+31.0%−3.6%
The marketbroad US ETFs+0.8%+2.6%+14.6%+16.8%+22.9%+12.9%

1M, 3M, 1Y, 3Y, 5Y: one month to five years. YTD: year to date. * A year, annualised. A dash means the ETF has not traded for the whole period. Since it started trading on October 1, 2025: −2.4% a year.

$10,000 invested October 31, 2025

ARKT $9,752Pure narrative flow $10,005The market $11,485
$0$10,000$20,000Oct 2025Apr 2026$0$10,000$20,000Oct 2025

Total return on the market price, with each distribution reinvested on its ex-date. Not the NAV return the issuer publishes; the two differ when the ETF trades above or below the value of its holdings. The narrative is the asset-weighted return of the unlevered ETFs that carry it. The market is the asset-weighted return of broad US index ETFs. Past performance is no guarantee of future results.

Common questions

What story is ARKT selling?

ARKT’s main story is pure narrative flow, which covers disruptive innovation, online consumers, betting and stocks chosen by social sentiment: where the retail crowd puts its money. Its second is the biology trade.

Which ETFs compete with ARKT?

The ETFs whose weekly returns move most like ARKT’s over the past 3 years are ARKK (0.99), OARK (0.97) and ARKW (0.91).

How has ARKT performed against its story?

Over the past year ARKT returned −3.3%, the ETFs carrying pure narrative flow −0.4% and broad US ETFs +16.8%, to October 2, 2026. Its weekly returns have a correlation of 0.99 with the story. Past performance only.

Run an ETF in pure narrative flow? StoryVector shows issuers where their ETFs stand against the closest rivals, every week.

Request a pilot
Narrative figures are from the weekly board. Performance is market price total return as of October 2, 2026. Assets are StoryVector’s weekly figure. Classification and measurement. Not investment advice. How the measurement works →